CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

Description

The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum. This study has two hypotheses: 1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds. 2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

Conditions

Cystic Fibrosis

Study Overview

Study Details

Study overview

The investigators will collect samples of sputum from healthy volunteers and patients with cystic fibrosis for the purpose of: a) purifying airway mucins for plate-based binding studies and; b) assessment of the effects of carbohydrates on the rheologic properties of the sputum. This study has two hypotheses: 1. Lectins from Pseudomonas aeruginosa and Aspergillus fumigatus bind to airway mucins in a fucose-dependent manner, and this binding can be inhibited by fucosyl glycomimetic compounds. 2. Fucosyl glycomimetics will compete with Pseudomonas aeruginosa lectin (PA-IIL) and Aspergillus fumigatus lectin (AFL) and disrupt lectin-driven mucin cross-linking in CF sputum.

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment to Lung Mucin

CF And Effects of Drugs Mixed Ex Vivo With Sputum for Mucolytic Treatment

Condition
Cystic Fibrosis
Intervention / Treatment

-

Contacts and Locations

San Francisco

University of California, San Francisco, San Francisco, California, United States, 94143

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Healthy control subjects:
  • * Age 18-65
  • * No history of lung disease
  • * Cystic fibrosis subjects:
  • * Age 18-65
  • * No history of lung disease other than cystic fibrosis
  • * Diagnosis of CF if sweat chloride values \> 60 mM on two separate pilocarpine iontophoresis sweat tests and/or two allelic CF-producing mutations in genetic analysis
  • * Use of recreational drugs within 30 days prior to enrollment
  • * Use of tobacco within 30 days prior to enrollment, or \> 10 pack-year tobacco history
  • * Pregnant or lactating females

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, San Francisco,

John V Fahy, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2024-04